Merck & Co., Inc. (NYSE:MRK) Stock Rating Upgraded by Morgan Stanley

Merck & Co., Inc. (NYSE:MRK) was upgraded by equities researchers at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a report issued on Thursday,Benzinga reports. The brokerage presently has a $179.00 price objective on the stock, up from their prior price objective of $116.00. Morgan Stanley’s target price suggests a potential upside of 17.60% from the stock’s previous close.

A number of other research analysts have also recently commented on MRK. JPMorgan Chase & Co. upped their price objective on Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, July 13th. BMO Capital Markets lifted their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Monday, July 20th. Argus increased their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, Jefferies Financial Group cut Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and an average target price of $138.80.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $152.21 on Thursday. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The firm’s 50-day moving average is $126.86 and its two-hundred day moving average is $120.74. Merck & Co., Inc. has a 12 month low of $77.58 and a 12 month high of $153.50. The company has a market capitalization of $375.53 billion, a PE ratio of 121.77, a price-to-earnings-growth ratio of 5.83 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. The business had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts predict that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Insider Transactions at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. This represents a 21.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of Merck & Co., Inc. stock in a transaction on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. The trade was a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently bought and sold shares of MRK. Kingdom Financial Group LLC. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc purchased a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $26,000. High Note Wealth LLC boosted its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after buying an additional 109 shares during the period. Finally, IFC & Insurance Marketing Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter worth $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination of Moderna’s individualized vaccine, intismeran, and Keytruda significantly extended the time high-risk melanoma patients remained free of recurrence and reduced the risk of cancer spreading compared with Keytruda alone. The result is viewed as the first positive late-stage validation of a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The data strengthen Merck’s oncology pipeline and could help offset concerns about the expected expiration of Keytruda’s patent later this decade. The companies are also studying similar vaccine approaches in lung, pancreatic, breast and other cancers, potentially expanding the commercial opportunity if regulators approve the treatment; approval is targeted for 2027. Moderna, Merck breakthrough could usher in wave of cancer vaccines
• Positive Sentiment: Investor enthusiasm was reflected in unusually heavy options activity, with 68,587 Merck call options purchased—about 188% above typical daily volume—suggesting increased bullish speculation, though options activity is not a fundamental performance measure.
• Neutral Sentiment: Broader bond-market relief supported interest-rate-sensitive equities and healthcare stocks, providing a favorable market backdrop for MRK. Stock Market Today, Aug. 19
• Negative Sentiment: Jefferies downgraded MRK from “strong buy” to “hold.” The call could limit further upside and reflects a more cautious analyst view after the stock’s strong run toward its 52-week high, although the firm’s specific rationale was not provided.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.